Finance

Beta
Ask
Lists
CABA:NASDAQ
Cabaletta Bio Inc
$3.01
+5.99%
(+0.17) 1D
$3.01
0.00% (0.00)
Pre-market
Closed: Jun 22, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CABA...
Open
$2.99
High
$3.07
Low
$2.91
Mkt. cap
490.79M
Avg. vol.
4.26M
Volume
2.75K
52-wk high
$4.23
52-wk low
$1.26
EPS
-$1.96
Beta
3.21
Shares outstanding
163.06M
No. of employees
157
Open
$2.99
High
$3.07
Low
$2.91
Mkt. cap
490.79M
Avg. vol.
4.26M
Volume
2.75K
52-wk high
$4.23
52-wk low
$1.26
EPS
-$1.96
Beta
3.21
Shares outstanding
163.06M
No. of employees
157
News stories
From sources across the web
About Cabaletta Bio Inc
CEO-
Employees157
Founded2017
HeadquartersPhiladelphia, Pennsylvania, United States
SectorBiotechnology
Websitecabalettabio.com
Analyst Ratings
Based on 7 analysts giving stock ratings to CABA in the past 3 months
Strong Buy
Buy
6
Hold
1
Sell
0
12 month forecast
Based on 7 Wall Street analysts offering 12 month price targets for CABA in the last 3 months.
Highest
Current $3.01
$30.00 (+896.68%)
Average
$15.75 (+423.26%)
Lowest
$4.00 (+32.89%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
-
-
06/08/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Maintained
$30.00
+896.7%
06/06/2026
Michael Ulz
Morgan Stanley
Buy
Maintained
$13.00
+331.9%
06/03/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
06/03/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
06/03/2026
Unknown Analyst
Wells Fargo
Hold
Reiterated
$4.00
+32.9%
05/15/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$16.00
+431.6%
05/15/2026
Roger Song
Jefferies
Buy
Maintained
$14.00
+365.1%
03/23/2026
Last report
May 14, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.39 / -$0.39
-0.47%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
37.64M
39.82M
36.19M
37.35M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.27M
6.76M
6.42M
6.94M
Operating expense
45.91M
46.59M
42.61M
44.30M
Total operating expenses
45.91M
46.59M
42.61M
44.30M
Operating income
-45.91M
-46.59M
-42.61M
-44.30M
Other non operating income
-61.00K
498.00K
-79.00K
341.00K
EBT including unusual items
-45.13M
-44.87M
-41.92M
-43.52M
EBT excluding unusual items
-45.13M
-44.87M
-41.92M
-43.52M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-45.13M
-44.87M
-41.92M
-43.52M
Net profit margin
-
-
-
-
Earnings per share
-0.73
-0.44
-0.40
-0.39
Interest and investment income
1.41M
1.81M
1.33M
1.08M
Interest expense
-571.00K
-584.00K
-555.00K
-636.00K
Net interest expenses
839.00K
1.22M
771.00K
440.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-45.44M
-46.24M
-42.26M
-43.96M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer